Cocrystal Pharma Inc./$COCP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Ticker
$COCP
Sector
Primary listing
Employees
10
Headquarters
Website
COCP Metrics
BasicAdvanced
$13m
-
-$0.72
1.50
-
Price and volume
Market cap
$13m
Beta
1.5
52-week high
$2.67
52-week low
$0.86
Average daily volume
121k
Financial strength
Current ratio
2.664
Quick ratio
2.443
Long term debt to equity
26.263
Total debt to equity
34.597
Profitability
EBITDA (TTM)
-8.975
Gross margin (TTM)
-2,151.56%
Net profit margin (TTM)
-3,924.00%
Operating margin (TTM)
-4,015.11%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-62.44%
Return on equity (TTM)
-154.62%
Valuation
Price to revenue (TTM)
52.642
Price to book
3.25
Price to tangible book (TTM)
3.25
Price to free cash flow (TTM)
-1.557
Free cash flow yield (TTM)
-64.21%
Free cash flow per share (TTM)
-0.624
Growth
Earnings per share change (TTM)
-53.52%
10-year revenue growth (CAGR)
16.00%
3-year earnings per share growth (CAGR)
-47.10%
10-year earnings per share growth (CAGR)
-28.47%
COCP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs